{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:06:02Z","timestamp":1761717962994},"reference-count":45,"publisher":"Frontline Medical Communications, Inc.","issue":"1","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cutaneous Medicine and Surgery"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.sder.2005.01.007","type":"journal-article","created":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T13:30:03Z","timestamp":1111671003000},"page":"2-9","source":"Crossref","is-referenced-by-count":5,"title":["Overview of biologic agents in medicine and dermatology"],"prefix":"10.12788","volume":"24","author":[{"given":"Jeffrey M.","family":"Sobell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","reference":[{"key":"10.1016\/j.sder.2005.01.007_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00128071-200203030-00003","article-title":"Novel therapies for psoriasis","volume":"3","author":"Cather","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.120568","article-title":"The immunologic basis for the treatment of psoriasis with new biologic agents","volume":"46","author":"Krueger","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archderm.138.5.657","article-title":"Biologic therapy for psoriasis","volume":"138","author":"Singri","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib4","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/clinchem\/48.12.2270","article-title":"Insulin","volume":"48","author":"Rosenfeld","year":"2002","journal-title":"Clin Chem"},{"issue":"Suppl 3","key":"10.1016\/j.sder.2005.01.007_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diacare.16.3.4","article-title":"The history of insulin","volume":"16","author":"Bliss","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.sder.2005.01.007_bib6","first-page":"S9","article-title":"Human insulin","volume":"46","author":"The","year":"1989","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.sder.2005.01.007_bib7","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0022-3476(97)70002-7","article-title":"Pioneering recombinant growth hormone manufacturing","volume":"131","author":"Cronin","year":"1997","journal-title":"J Pediatr"},{"key":"10.1016\/j.sder.2005.01.007_bib8","first-page":"2586","article-title":"Value of monoclonal antibody OKT 3 in solid organ transplantation","volume":"24","author":"Carrier","year":"1992","journal-title":"Transplant Proc"},{"key":"10.1016\/j.sder.2005.01.007_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cld.2004.02.004","article-title":"Treatment of hepatitis B with interferon and combination therapy","volume":"8","author":"Cooksley","year":"2004","journal-title":"Clin in Liver Dis"},{"key":"10.1016\/j.sder.2005.01.007_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1470-2045(03)00980-X","article-title":"Advances in the treatment of hairy-cell leukaemia","volume":"4","author":"Mey","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.sder.2005.01.007_bib11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2005.01.007_bib12","first-page":"250","article-title":"Hematopoietic growth factors in cancer chemotherapy","volume":"18","author":"Crawford","year":"1999","journal-title":"Cancer Chemother Biol Response Modif"},{"key":"10.1016\/j.sder.2005.01.007_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev.med.50.1.291","article-title":"Immunologic therapy of multiple sclerosis","volume":"50","author":"Arnason","year":"1999","journal-title":"Ann Rev Med"},{"key":"10.1016\/j.sder.2005.01.007_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/14779072.2.2.285","article-title":"Intra-arterial thrombolysis in acute ischemic stroke","volume":"2","author":"Pettersen","year":"2004","journal-title":"Exp Rev Cardiovasc Ther"},{"key":"10.1016\/j.sder.2005.01.007_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1517\/14712598.4.3.375","article-title":"Monoclonal antibody therapy of B cell lymphoma","volume":"4","author":"Weiner","year":"2004","journal-title":"Exp Op Biol Ther"},{"key":"10.1016\/j.sder.2005.01.007_bib16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1309\/5CWPU41AFR1VYM3F","article-title":"Targeted therapies for cancer 2004","volume":"122","author":"Ross","year":"2004","journal-title":"Am J Clin Path"},{"key":"10.1016\/j.sder.2005.01.007_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00000441-200302000-00005","article-title":"New indications for treatment of chronic inflammation by TNF-alpha blockade","volume":"325","author":"Reimold","year":"2003","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.sder.2005.01.007_bib18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1749-6632.2001.tb03720.x","article-title":"Interleukin-2 fusion toxin","volume":"941","author":"Foss","year":"2001","journal-title":"Ann New York Acad Sci"},{"key":"10.1016\/j.sder.2005.01.007_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.det.2004.03.014","article-title":"Current concepts and review of alefacept in the treatment of psoriasis","volume":"22","author":"Krueger","year":"2004","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.sder.2005.01.007_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.det.2004.03.015","article-title":"Current concepts and review of efalizumab in the treatment of psoriasis","volume":"22","author":"Leonardi","year":"2004","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.sder.2005.01.007_bib21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","article-title":"Psoriasis\u2014epidemiology and clinical spectrum","volume":"26","author":"Christophers","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/mjd.2000.106374","article-title":"Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?","volume":"43","author":"Krueger","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib23","first-page":"280","article-title":"The impact of psoriasis on Quality of Life","volume":"137","author":"Kreuger","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1067\/mjd.2002.122755","article-title":"Identifying the harmful effect of psoriasis on health related quality of life","volume":"47","author":"Weiss","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib25","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis","volume":"38","author":"Roenigk","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0190-9622(87)80490-5","article-title":"Pancytopenia induced by interaction between methotrexate and trimethoprim-sulfamethoxazole","volume":"17","author":"Thomas","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00128071-200001010-00003","article-title":"Risk-benefit assessment of methotrexate in the treatment of severe psoriasis","volume":"1","author":"Kujipers","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00296-001-0166-7","article-title":"Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis","volume":"21","author":"Sarzi-Puttini","year":"2002","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.sder.2005.01.007_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2230.2002.00998.x","article-title":"Adverse effects with long-term cyclosporin for severe psoriasis","volume":"27","author":"Markham","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib30","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0190-9622(99)70359-2","article-title":"Acitretin in psoriasis","volume":"41","author":"Katz","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib31","series-title":"Phototherapy and Photochemotherapy of Skin Disease","author":"Morison","year":"1990"},{"key":"10.1016\/j.sder.2005.01.007_bib32","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1067\/mjd.2001.114576","article-title":"The PUVA. Follow up study. The risk of melanoma in association with long-term exposure to PUVA","volume":"44","author":"Stern","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1067\/mjd.2002.124618","article-title":"The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis","volume":"47","author":"Stern","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/0190-9622(93)70067-4","article-title":"An approach to the treatment of moderate to severe psoriasis with rotational therapy","volume":"28","author":"Weinstein","year":"1993","journal-title":"J Amer Acad Derm"},{"key":"10.1016\/j.sder.2005.01.007_bib35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.sder.2005.01.007_bib36","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","article-title":"The Majority of epidermal t-cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-\u03b3, interleukin-2, and tumor necrosis factor-\u03b1, defining TC1 (cytotoxic t lymphocyte) and TH1 effector populations","volume":"113","author":"Austin","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib37","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0190-9622(03)01134-4","article-title":"The immunology of psoriasis and biologic immunotherapy","volume":"49","author":"Mehlis","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2005.01.007_bib38","unstructured":"Freimanis R (ed): USAN: United States Adopted Names Council Handbook (ed 5). Chicago, Illinois, United States Pharmacopeial Convention"},{"key":"10.1016\/j.sder.2005.01.007_bib39","unstructured":"Papp KA, Gulliver WP, Monroe E, et al: Retreatment of moderate to severe psoriasis with subcutaneous efalizumab (anti-CD11a): Results from an open-label study. Poster presented at: Meeting of the American Academy of Dermatology; New Orleans, LA; March 2002 (poster)"},{"key":"10.1016\/j.sder.2005.01.007_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/biol.1994.1015","article-title":"Plasmid integration, amplification and cytogenetics in CHO cells","volume":"22","author":"Wurm","year":"1994","journal-title":"Biologicals"},{"key":"10.1016\/j.sder.2005.01.007_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/biol.1994.1014","article-title":"The molecular biology of production cell lines","volume":"22","author":"Simonsen","year":"1994","journal-title":"Biologicals"},{"key":"10.1016\/j.sder.2005.01.007_bib42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/biol.1994.1019","article-title":"Mammalian cell culture systems for recombinant protein production","volume":"22","author":"Birch","year":"1994","journal-title":"Biologicals"},{"key":"10.1016\/j.sder.2005.01.007_bib43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/biol.1994.1020","article-title":"Protein purification","volume":"22","author":"Berthold","year":"1994","journal-title":"Biologicals"},{"key":"10.1016\/j.sder.2005.01.007_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1006\/biol.1994.1021","article-title":"The quality control of biotechnology products","volume":"22","author":"Federici","year":"1994","journal-title":"Biologicals"},{"key":"10.1016\/j.sder.2005.01.007_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/biol.1998.0153","article-title":"WHO Requirements for the Use of Animal Cells as in vitro Substrates for the Production of Biologicals","volume":"26","year":"1998","journal-title":"Biologicals"}],"container-title":["Seminars in Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562905000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562905000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scmsjournal.com\/wp-content\/uploads\/2016\/08\/v24i1-Sobell.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T15:09:20Z","timestamp":1616166560000},"score":1,"resource":{"primary":{"URL":"http:\/\/scmsjournal.com\/article\/buy_now\/?id=483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S1085562905000088"],"URL":"https:\/\/doi.org\/10.1016\/j.sder.2005.01.007","relation":{},"ISSN":["1085-5629"],"issn-type":[{"value":"1085-5629","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}